These medications have transformed the lives of many patients by helping control Type 2 diabetes and supporting significant weight loss
10.1016/S0140-6736(11)61215-4
Cao T, Xie R, Wang J, Xiao M, Wu H, Liu X, et al
"Medicare Part D Coverage of Anti-obesity Medications: A Call for Policy Change." JAMA Internal Medicine
The field is rapidly moving beyond single-target GLP-1 agonism: dual and triple agonists, combining GLP-1 with receptors for GIP and/or glucagon, are designed to produce larger weight loss and beneficial metabolic effects
Ella amplifica y optimiza la combustin de grasas, pero no crea un dficit calrico de la nada